{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Meng L"],"funding":["Shanghai Municipal Science and Technology Major Project","Key Technologies Research and Development Program","CAS Strategic Priority Research Program","Institut Pasteur International Network","National Natural Science Foundation of China","Innovation Capacity Building Project of Jiangsu province"],"pagination":["e1011085"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9907810"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(1)"],"pubmed_abstract":["Neutralizing antibodies (nAbs) are important assets to fight COVID-19, but most existing nAbs lose the activities against Omicron subvariants. Here, we report a human monoclonal antibody (Ab08) isolated from a convalescent patient infected with the prototype strain (Wuhan-Hu-1). Ab08 binds to the receptor-binding domain (RBD) with pico-molar affinity (230 pM), effectively neutralizes SARS-CoV-2 and variants of concern (VOCs) including Alpha, Beta, Gamma, Mu, Omicron BA.1 and BA.2, and to a lesser extent for Delta and Omicron BA.4/BA.5 which bear the L452R mutation. Of medical importance, Ab08 shows therapeutic efficacy in SARS-CoV-2-infected hACE2 mice. X-ray crystallography of the Ab08-RBD complex reveals an antibody footprint largely in the β-strand core and away from the ACE2-binding motif. Negative staining electron-microscopy suggests a neutralizing mechanism through which Ab08 destructs the Spike trimer. Together, our work identifies a nAb with therapeutic potential for COVID-19."],"journal":["PLoS pathogens"],"pubmed_title":["A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy."],"pmcid":["PMC9907810"],"funding_grant_id":["XDB37020204","BM2020019","2021YFE0200600","SARS-CoV-2 Project","2019SHZDZX02","82151215","HS2021SHZX001","XDPB0303"],"pubmed_authors":["Cao L","Yang H","Jiang L","Zhu Y","Zhang J","Li D","Gu Z","Lavillette D","Tang H","Lu L","Feng J","Li T","Zhou B","Zhang X","Zha J","Meng L","Jiang C"],"additional_accession":[]},"is_claimable":false,"name":"A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy.","description":"Neutralizing antibodies (nAbs) are important assets to fight COVID-19, but most existing nAbs lose the activities against Omicron subvariants. Here, we report a human monoclonal antibody (Ab08) isolated from a convalescent patient infected with the prototype strain (Wuhan-Hu-1). Ab08 binds to the receptor-binding domain (RBD) with pico-molar affinity (230 pM), effectively neutralizes SARS-CoV-2 and variants of concern (VOCs) including Alpha, Beta, Gamma, Mu, Omicron BA.1 and BA.2, and to a lesser extent for Delta and Omicron BA.4/BA.5 which bear the L452R mutation. Of medical importance, Ab08 shows therapeutic efficacy in SARS-CoV-2-infected hACE2 mice. X-ray crystallography of the Ab08-RBD complex reveals an antibody footprint largely in the β-strand core and away from the ACE2-binding motif. Negative staining electron-microscopy suggests a neutralizing mechanism through which Ab08 destructs the Spike trimer. Together, our work identifies a nAb with therapeutic potential for COVID-19.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-05-28T08:04:03.574Z","creation":"2025-04-04T08:35:16.555Z"},"accession":"S-EPMC9907810","cross_references":{"pubmed":["36706160"],"doi":["10.1371/journal.ppat.1011085"]}}